

Supplementary materials




Figure S1 Log odds ratio of colorectal cancer risk according to polygenic risk score level. OR, odds ratio; PRS, polygenic risk score.




Figure S2 Boxplot of polygenic risk scores among colorectal cancer cases and controls. CRC, colorectal cancer; PRS, polygenic risk score.

Table S1 Composition and points for the diet quality score, on the basis of responses from the DACHS study food frequency questionnaire

| Food groups | Food frequency questionnaire responses | | | | | | Total maximum |
|-------------------------------------|--|--------------|-------------------------|---------------|-------------------------|-------|---------------|
| | Multiple times per day | Once per day | Multiple times per week | Once per week | Less than once per week | Never | |
| Red and processed meat ¹ | 0 | 1 | 2 | 3 | 4 | 5 | 5 |
| Fish | 5 | 4 | 3 | 2 | 1 | 0 | 5 |
| Whole grains ² | 10 | 8 | 6 | 4 | 2 | 0 | 10 |
| Dairy foods ³ | 10 | 8 | 6 | 4 | 2 | 0 | 10 |
| Fruit | 10 | 8 | 6 | 4 | 2 | 0 | 10 |
| Vegetables/salad | 10 | 8 | 6 | 4 | 2 | 0 | 10 |
| | | | | | | | 50 |

Note: This table was developed by Carr et al. (PMID: 30201362; PMID: 32179093). ¹Red and processed meat: fresh pork, beef, etc., sausages made from beef or pork, luncheon meats (e.g., salami/sliced sausage), or ham. ²Whole grains and whole grain products: e.g., whole grain bread, muesli, or other whole grain products. ³Dairy foods: cheese or quark, yogurt, or milk.

Table S2 Description of the individual lifestyle factors comprising the healthy lifestyle score

| Lifestyle factor | Points | Description |
|---------------------|--------|--|
| Smoking | 0 | Smoking: current smoker or former smoker (≥ 30 pack years) |
| | 1 | Non-smoking: never smoker or former smoker (< 30 pack years) |
| Alcohol consumption | 0 | Did not meet recommendations on alcoholic drinks ¹ |
| | 1 | Met recommendation on alcoholic drinks ¹ |
| Diet quality | 0 | Unhealthy diet quality: diet score ² $<$ diet score in the highest 40% |
| | 1 | Healthy diet quality: diet score ² \geq diet score in the highest 40% |
| Physical activity | 0 | Did not meet physical activity guidelines ³ |
| | 1 | Met physical activity guidelines ³ |
| Body mass index | 0 | Overweight or obese (BMI ≥ 25 kg/m ²) |
| | 1 | Healthy weight (18.5 $<$ BMI $<$ 25 kg/m ²) |

Note: This table was developed by Carr et al. (PMID: 30201362; PMID: 32179093). ¹World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) (2007) Recommendation on alcoholic drinks: ≤ 24 g/day for men and ≤ 12 g/day for women. ²Calculated on the basis of data from the Food Frequency Questionnaires according to the updated evidence from the 2017 WCRF/AICR diet recommendations for CRC prevention. ³The World Health Organization Global Recommendations on Physical Activity for Health (2010) recommend that adults engage in at least 150 min of moderate-intensity or 75 min of vigorous-intensity aerobic physical activity throughout the week, or an equivalent combination of moderate and vigorous intensity physical activity (at least ~ 500 MET minutes). BMI, body mass index.

Table S3 Information on genotyping and imputation

| Genotyping platform | CRC cases (n) | Controls (n) | Recruitment Period | Imputation |
|---------------------------------|---------------|--------------|--------------------|--|
| Illumina HumanCytoSNP | 1,588 | 1640 | 2003–2008 | |
| Illumina HumanOmniExpress | 649 | 473 | 2007–2010 | |
| Illumina HumanOmniExpress | 1,128 | 596 | 2010–2015 | Haplotype Reference Consortium (version r1.1.2016) |
| Illumina Infinium OncoArray | 858 | 626 | 2003–2016 | |
| Illumina Global Screening Array | 621 | 629 | 2016–2017 | |

Note: We excluded triallelic SNPs, genotyped SNPs that had a low call rate (< 98%), lack of Hardy-Weinberg equilibrium in control individuals ($P < 1 \times 10^{-4}$), or low minor allele frequency (< 0.1%), and those not assigned an rs number. More details can be found in previous studies by Peters et al.¹ and Schumacher et al.². ¹Peters U, Jiao S, Schumacher FR, et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. *Gastroenterology* 2013; 144:799–807. ²Schumacher FR, Schmit SL, Jiao S, et al. Genome-wide association study of colorectal cancer identifies 6 new susceptibility loci. *Nat Commun* 2015; 6:7138.

Table S4 Overview of colorectal cancer related single-nucleotide polymorphisms identified in genome-wide association studies and considered in this analysis

| SNP | Locus | Position | Risk allele | Beta |
|-------------|---------|-----------|-------------|--------|
| rs4360494 | 1p34.3 | 38455891 | G | 0.0379 |
| rs12144319 | 1p32.3 | 55246035 | C | 0.0661 |
| rs72647484 | 1p36.12 | 22587728 | T | 0.0504 |
| rs7542665 | 1p31.3 | 62673037 | C | 0.0334 |
| rs6678517 | 1q25.3 | 183002639 | A | 0.073 |
| rs17011141 | 1q41 | 222112634 | G | 0.0877 |
| rs448513 | 2q24.2 | 159964552 | C | 0.0054 |
| rs11884596 | 2q33.1 | 199612407 | C | 0.0342 |
| rs983402 | 2q33.1 | 199781586 | T | 0.0622 |
| rs7606562 | 2p16.3 | 48686695 | T | 0.0414 |
| rs11692435 | 2q11.2 | 98275354 | G | 0.0492 |
| rs3731861 | 2q35 | 219191256 | T | 0.0613 |
| rs10049390 | 3q22.2 | 133701119 | A | 0.0455 |
| rs13086367 | 3q13.2 | 112903888 | A | 0.0463 |
| rs72942485 | 3q13.2 | 112999560 | G | 0.0545 |
| rs9831861 | 3p21.1 | 53088285 | G | 0.0294 |
| rs35470271 | 3p22.1 | 40915239 | G | 0.0994 |
| rs12635946 | 3q13.2 | 112916918 | C | 0.0334 |
| rs113569514 | 3q22.2 | 133748789 | T | 0.0414 |
| rs9876206 | 3q26.2 | 169517436 | C | 0.0453 |
| rs6781752 | 3p14.1 | 66365163 | A | 0.0597 |
| rs11727676 | 4q31.21 | 145659064 | C | 0.0093 |
| rs1391441 | 4q24 | 106128760 | A | 0.0148 |

Table S4 Continued

| SNP | Locus | Position | Risk allele | Beta |
|------------------------|---------|-----------|-------------|--------|
| rs13149359 | 4q22.2 | 94938618 | A | 0.052 |
| rs7708610 | 5p13.1 | 40102443 | A | 0.0384 |
| rs78368589 | 5p15.33 | 1240204 | T | 0.0786 |
| rs145364999 | 5q21.1 | 98206082 | T | 0.3496 |
| rs2735940 | 5p15.33 | 1296486 | G | 0.0865 |
| rs12514517 | 5p13.1 | 40280076 | A | 0.1013 |
| rs755229494 | 5q22.2 | 112097351 | G | 0.6286 |
| rs12659017 | 5q23.2 | 125988175 | G | 0.0374 |
| rs4976270 | 5q31.1 | 134467220 | C | 0.0693 |
| rs13204733 | 6p12.1 | 55566108 | G | 0.0643 |
| rs116685461 | 6p21.33 | 31315512 | G | 0.0655 |
| rs9271695 | 6p21.32 | 32593080 | G | 0.0889 |
| rs2516420 | 6p21.33 | 31449620 | C | 0.1091 |
| rs116353863 | 6p21.33 | 31010185 | C | 0.1202 |
| rs16878812 | 6p21.31 | 35569562 | A | 0.0778 |
| rs9470361 | 6p21.2 | 36623379 | A | 0.054 |
| rs62404966 | 6p12.1 | 55712124 | C | 0.0724 |
| rs3131043 | 6p21.33 | 30758466 | G | 0.0294 |
| rs2070699 | 6p24.1 | 12292772 | T | 0.0294 |
| rs1476570 | 6p22.1 | 29809860 | A | 0.0492 |
| rs3830041 | 6p21.32 | 32191339 | T | 0.0645 |
| rs6928864 ¹ | 6q21 | 105966894 | C | 0.0531 |
| rs62396735 | 6p21.1 | 41702582 | C | 0.033 |
| rs12672022 | 7p13 | 45136423 | T | 0.0067 |

Table S4 Continued

| SNP | Locus | Position | Risk allele | Beta |
|-------------|----------|-----------|-------------|--------|
| rs80077929 | 7p12.3 | 46094089 | T | 0.0093 |
| rs10951878 | 7p12.3 | 46926695 | C | 0.0531 |
| rs3801081 | 7p12.3 | 47511161 | G | 0.0253 |
| rs7013278 | 8q24.21 | 128414892 | T | 0.0091 |
| rs4313119 | 8q24.21 | 128571855 | G | 0.0518 |
| rs16892766 | 8q23.3 | 117630683 | C | 0.2099 |
| rs6469654 | 8q23.3 | 117632965 | G | 0.0677 |
| rs117079142 | 8q24.11 | 117790914 | A | 0.1139 |
| rs6983267 | 8q24.21 | 128413305 | G | 0.1052 |
| rs34405347 | 9q22.33 | 101679752 | T | 0.0089 |
| rs1537372 | 9p21.3 | 22103183 | G | 0.012 |
| rs10980628 | 9q31.3 | 113671403 | C | 0.0511 |
| rs12217641 | 10p14 | 8663875 | C | 0.0069 |
| rs10786560 | 10q24.2 | 101315166 | G | 0.0082 |
| rs1250567 | 10q22.3 | 81046265 | C | 0.047 |
| rs11255841 | 10p14 | 8739580 | T | 0.1064 |
| rs10821907 | 10q11.23 | 52648454 | C | 0.073 |
| rs704017 | 10q22.3 | 80819132 | G | 0.0765 |
| rs11190164 | 10q24.2 | 101351704 | G | 0.0889 |
| rs12246635 | 10q25.2 | 114288619 | C | 0.0975 |
| rs11196170 | 10q25.2 | 114722621 | A | 0.0527 |
| rs7946853 | 11q13.4 | 74409077 | C | 0.0119 |
| rs55864876 | 11q22.1 | 100717136 | G | 0.015 |
| rs2186607 | 11q22.1 | 101656397 | T | 0.0483 |
| rs61389091 | 11q13.4 | 74427921 | C | 0.1934 |
| rs4450168 | 11p15.4 | 10286755 | C | 0.0413 |
| rs174533 | 11q12.2 | 61549025 | G | 0.0636 |
| rs7121958 | 11q13.4 | 74280012 | G | 0.078 |
| rs3087967 | 11q23.1 | 111156836 | T | 0.1122 |
| rs4759277 | 12q13.3 | 57533690 | A | 0.0285 |
| rs1427760 | 12q24.21 | 115100714 | C | 0.0424 |
| rs3217874 | 12p13.32 | 4400808 | T | 0.0453 |
| rs10849433 | 12p13.31 | 6406904 | C | 0.0468 |
| rs11610543 | 12q12 | 43134191 | G | 0.0474 |
| rs35808169 | 12p13.32 | 4368607 | C | 0.089 |

Table S4 Continued

| SNP | Locus | Position | Risk allele | Beta |
|-------------|----------|-----------|-------------|--------|
| rs3217810 | 12p13.32 | 4388271 | T | 0.1181 |
| rs2250430 | 12p13.31 | 6421174 | T | 0.0597 |
| rs77969132 | 12p11.21 | 31594813 | T | 0.1583 |
| rs12372718 | 12q13.12 | 51171090 | G | 0.0896 |
| rs597808 | 12q24.12 | 111973358 | G | 0.0737 |
| rs7300312 | 12q24.21 | 115890922 | C | 0.066 |
| rs2710310 | 12p13.2 | 12035649 | C | 0.0145 |
| rs78341008 | 13q22.1 | 73791554 | C | 0.0109 |
| rs8000189 | 13q34 | 111075881 | T | 0.0473 |
| rs45597035 | 13q22.1 | 73649152 | A | 0.0495 |
| rs1924816 | 13q22.1 | 73997961 | A | 0.0506 |
| rs7333607 | 13q13.3 | 37462010 | G | 0.0758 |
| rs1330889 | 13q22.3 | 78609615 | C | 0.0453 |
| rs377429877 | 13q13.2 | 34092164 | C | 0.0468 |
| rs1951864 | 14q22.2 | 54369299 | A | 0.0059 |
| rs17094983 | 14q23.1 | 59189361 | G | 0.0062 |
| rs8020436 | 14q23.1 | 59208437 | A | 0.0294 |
| rs35107139 | 14q22.2 | 54419106 | C | 0.0912 |
| rs4901473 | 14q22.2 | 54445157 | G | 0.0465 |
| rs745213 | 15q23 | 68060389 | G | 0.0072 |
| rs12594720 | 15q22.31 | 67007018 | C | 0.0246 |
| rs56324967 | 15q22.33 | 67402824 | C | 0.0689 |
| rs17816465 | 15q13.3 | 33156386 | A | 0.069 |
| rs12708491 | 15q13.3 | 32992836 | G | 0.0464 |
| rs2293581 | 15q13.3 | 33010736 | A | 0.1248 |
| rs7495132 | 15q26.1 | 91172901 | T | 0.0453 |
| rs9930005 | 16q23.2 | 80043258 | C | 0.0061 |
| rs12447408 | 16q24.1 | 86252544 | A | 0.0079 |
| rs9924886 | 16q22.1 | 68743939 | A | 0.055 |
| rs12149163 | 16q24.1 | 86339315 | T | 0.0487 |
| rs62042090 | 16q24.1 | 86703949 | T | 0.0481 |
| rs983318 | 17q24.3 | 70413253 | A | 0.0397 |
| rs73975586 | 17p13.3 | 814243 | A | 0.0497 |
| rs1078643 | 17p12 | 10707241 | A | 0.0747 |
| rs75954926 | 17q25.3 | 81061048 | G | 0.0882 |

Table S4 Continued

| SNP | Locus | Position | Risk allele | Beta |
|-------------|----------|----------|-------------|--------|
| rs373585858 | 17q25.3 | 80394556 | A | 0.1103 |
| rs4968127 | 17p13.3 | 809643 | G | 0.0514 |
| rs11874392 | 18q21.1 | 46453156 | A | 0.1606 |
| rs73068325 | 19q13.43 | 59079096 | T | 0.0066 |
| rs34797592 | 19p13.11 | 16417198 | T | 0.0824 |
| rs28840750 | 19q13.11 | 33519927 | T | 0.1939 |
| rs1963413 | 19q13.2 | 41871573 | A | 0.0441 |
| rs12979278 | 19q13.33 | 49218602 | T | 0.0293 |
| rs2738783 | 20q13.33 | 62308612 | T | 0.006 |
| rs6067417 | 20q13.13 | 48983697 | C | 0.0331 |
| rs6031311 | 20q13.12 | 42666475 | T | 0.0362 |
| rs6091189 | 20q13.13 | 49256285 | T | 0.0549 |
| rs994308 | 20p12.3 | 6603622 | C | 0.0626 |
| rs28488 | 20p12.3 | 6762221 | T | 0.0714 |
| rs556532366 | 20p12.3 | 8568071 | T | 0.0715 |
| rs189583 | 20p12.3 | 6376457 | G | 0.0795 |
| rs4813802 | 20p12.3 | 6699595 | G | 0.0819 |
| rs11087784 | 20p12.3 | 7740976 | G | 0.0874 |
| rs6066825 | 20q13.13 | 47340117 | A | 0.0719 |
| rs6063514 | 20q13.13 | 49055318 | C | 0.0547 |
| rs13831 | 20q13.32 | 57475191 | G | 0.0334 |
| rs1741640 | 20q13.33 | 60932414 | C | 0.1146 |
| rs6058093 | 20q11.22 | 33213196 | C | 0.045 |

¹For building the PRS, the missing reference SNP was replaced by rs6904092 (linkage disequilibrium, $D' = 1$ and $r^2 = 1$). A, adenine; C, cytosine; G, guanine; OR, odds ratio; T, thymine; SNP, single-nucleotide polymorphism.

Table S5 Association of unweighted and weighted polygenic risk score with colorectal cancer risk

| PRS | PRS decile | CRC cases, <i>n</i> (%) | Controls, <i>n</i> (%) | OR (95% CI) ¹ | OR (95% CI) ² |
|----------------|------------|-------------------------|------------------------|--------------------------|--------------------------|
| Unweighted PRS | D1 | 215 (4.5) | 395 (10.0) | Ref. | Ref. |
| | D2 | 326 (6.8) | 399 (10.1) | 1.44 (1.13, 1.83) | 1.44 (1.14, 1.84) |
| | D3 | 334 (6.9) | 390 (9.9) | 1.63 (1.28, 2.07) | 1.64 (1.29, 2.08) |
| | D4 | 435 (9.0) | 399 (10.1) | 2.01 (1.60, 2.54) | 2.02 (1.60, 2.55) |
| | D5 | 372 (7.7) | 395 (10.0) | 1.92 (1.52, 2.44) | 1.93 (1.52, 2.44) |
| | D6 | 502 (10.4) | 387 (9.8) | 2.31 (1.84, 2.91) | 2.33 (1.85, 2.94) |
| | D7 | 604 (12.5) | 395 (10.0) | 2.79 (2.23, 3.51) | 2.82 (2.25, 3.55) |
| | D8 | 571 (11.9) | 395 (10.0) | 2.74 (2.18, 3.44) | 2.76 (2.20, 3.47) |
| | D9 | 617 (12.8) | 392 (9.9) | 2.87 (2.29, 3.60) | 2.87 (2.29, 3.60) |
| | D10 | 838 (17.4) | 394 (10.0) | 3.91 (3.14, 4.89) | 3.93 (3.15, 4.91) |
| Weighted PRS | D1 | 228 (4.7) | 395 (10.0) | Ref. | Ref. |
| | D2 | 291 (6.0) | 394 (10.0) | 1.32 (1.03, 1.68) | 1.31 (1.03, 1.67) |
| | D3 | 327 (6.8) | 394 (10.0) | 1.52 (1.20, 1.93) | 1.52 (1.20, 1.93) |
| | D4 | 397 (8.2) | 394 (10.0) | 1.85 (1.47, 2.34) | 1.85 (1.47, 2.33) |
| | D5 | 433 (9.0) | 394 (10.0) | 2.07 (1.64, 2.61) | 2.06 (1.63, 2.59) |
| | D6 | 492 (10.2) | 394 (10.0) | 2.26 (1.80, 2.84) | 2.26 (1.80, 2.84) |
| | D7 | 530 (11.0) | 394 (10.0) | 2.50 (1.99, 3.14) | 2.52 (2.01, 3.16) |
| | D8 | 578 (12.0) | 394 (10.0) | 2.64 (2.11, 3.31) | 2.64 (2.11, 3.31) |
| | D9 | 681 (14.1) | 394 (10.0) | 3.17 (2.54, 3.96) | 3.19 (2.55, 3.98) |
| | D10 | 857 (17.8) | 394 (10.0) | 3.89 (3.13, 4.85) | 3.89 (3.12, 4.84) |

¹Adjusted for smoking, alcohol intake, diet quality, physical activity, body mass index, age, gender, education, family history of CRC, history of colonoscopy, participation in routine health check-ups, and use of nonsteroidal anti-inflammatory drugs. ²Adjusted for healthy lifestyle score, age, gender, education, family history of CRC, history of colonoscopy, participation in routine health check-ups, and use of nonsteroidal anti-inflammatory drugs. CI, confidence interval; CRC, colorectal cancer; D, decile of PRS among controls; OR, odds ratio; PRS, polygenic risk score; Ref., reference.

Table S6 Frequency of the healthy lifestyle factors and agreement among the various healthy lifestyle factors in cases and controls

| Healthy lifestyle factor | CRC cases (<i>n</i> = 4,844) | | | | | Controls (<i>n</i> = 3,964) | | | | | | |
|--------------------------|-------------------------------|-------------------|------|-------|-------|------------------------------|--------------|-------------------|------|-------|--------|--------|
| | <i>n</i> (%) | Kappa coefficient | | | | | <i>n</i> (%) | Kappa coefficient | | | | |
| | | SMK | ALC | DQ | PA | BMI | | SMK | ALC | DQ | PA | BMI |
| SMK | 3,763 (77.7) | 1.00 | 0.13 | 0.085 | 0.035 | -0.027 | 3,258 (82.2) | 1.00 | 0.12 | 0.092 | 0.052 | -0.018 |
| ALC | 3,571 (73.7) | | 1.00 | 0.050 | 0.010 | 0.034 | 3,051 (77.0) | | 1.00 | 0.057 | -0.012 | 0.044 |
| DQ | 1,632 (33.7) | | | 1.00 | 0.044 | 0.079 | 1,813 (45.7) | | | 1.00 | 0.059 | 0.097 |
| PA | 4,084 (84.3) | | | | 1.00 | 0.040 | 3,474 (87.6) | | | | 1.00 | 0.033 |
| BMI | 1,441 (29.7) | | | | | 1.00 | 1,504 (37.9) | | | | | 1.00 |

Note: All healthy lifestyle factors were categorized into 2 subgroups according to pertinent health guidelines. ALC, alcohol intake; BMI, body mass index; CRC, colorectal cancer; DQ, diet quality; PA, physical activity; SMK, smoking.

Table S7 Associations of the healthy lifestyle score with colorectal cancer risk by polygenic risk score level

| PRS ¹ | Healthy lifestyle score | CRC cases, <i>n</i> (%) | Controls, <i>n</i> (%) | OR (95% CI) ² |
|------------------|-------------------------|-------------------------|------------------------|--------------------------|
| Low | 0–2 | 313 (30.5) | 264 (20.0) | Ref. |
| | 3 | 374 (36.5) | 457 (34.7) | 0.70 (0.55, 0.88) |
| | 4 | 273 (26.6) | 406 (30.8) | 0.58 (0.45, 0.74) |
| | 5 | 66 (6.4) | 190 (14.4) | 0.30 (0.21, 0.43) |
| | Per 1-point increase | | | 0.73 (0.67, 0.80) |
| Moderate | 0–2 | 479 (31.0) | 301 (22.9) | Ref. |
| | 3 | 564 (36.5) | 455 (34.7) | 0.82 (0.66, 1.00) |
| | 4 | 395 (25.6) | 380 (28.9) | 0.67 (0.54, 0.84) |
| | 5 | 106 (6.9) | 177 (13.5) | 0.43 (0.32, 0.59) |
| | Per 1-point increase | | | 0.80 (0.74, 0.87) |
| High | 0–2 | 727 (32.4) | 311 (23.7) | Ref. |
| | 3 | 777 (34.6) | 425 (32.4) | 0.79 (0.65, 0.96) |
| | 4 | 565 (25.2) | 389 (29.7) | 0.62 (0.50, 0.76) |
| | 5 | 175 (7.8) | 186 (14.2) | 0.39 (0.30, 0.52) |
| | Per 1-point increase | | | 0.78 (0.73, 0.84) |

¹PRS was categorized into low, moderate, and high levels according to tertiles of PRS among controls. ²Adjusted for age, gender, school education, family history of CRC, history of colonoscopy, participation in routine health check-ups, and use of nonsteroidal anti-inflammatory drugs, with healthy lifestyle score ≤ 2 points as the reference in each PRS subgroup. CI, confidence intervals; CRC, colorectal cancer; OR, odds ratio; PRS, polygenic risk score; Ref., reference.

Table S8 Association of the healthy lifestyle score with colorectal cancer risk, stratified by age and gender

| Variables | CRC cases, <i>n</i> (%) | Controls, <i>n</i> (%) | OR (95% CI) ¹ | GRE (95% CI) | <i>P</i> -interaction ² |
|---------------------------------------|-------------------------|------------------------|--------------------------|-----------------------|------------------------------------|
| Age < 55 years | | | | | 0.083 |
| Healthy lifestyle score | | | | | |
| 0–2 | 158 (29.1) | 78 (19.6) | Ref. | Ref. | |
| 3 | 203 (37.4) | 116 (29.1) | 0.96 (0.65, 1.40) | –3.3 (–34.6, 27.9) | |
| 4 | 128 (23.6) | 127 (31.9) | 0.51 (0.34, 0.77) | –55.1 (–95.2, –15.0) | |
| 5 | 54 (9.9) | 77 (19.3) | 0.38 (0.23, 0.63) | –79.2 (–131.1, –27.2) | |
| Per 1-point increase | | | 0.73 (0.64, 0.84) | –25.8 (–41.2, –10.3) | |
| PRS (per 10 percentile increase) | | | 1.13 (1.07, 1.18) | | |
| Age ≥ 55 years | | | | | |
| Healthy lifestyle score | | | | | |
| 0–2 | 1,361 (31.9) | 798 (22.5) | Ref. | Ref. | |
| 3 | 1,512 (35.4) | 1,221 (34.5) | 0.77 (0.68, 0.88) | –21.4 (–32.3, –10.4) | |
| 4 | 1,105 (25.9) | 1,048 (29.6) | 0.66 (0.57, 0.75) | –34.0 (–46.3, –21.7) | |
| 5 | 293 (6.9) | 476 (13.4) | 0.39 (0.32, 0.47) | –77.0 (–96.2, –57.9) | |
| Per 1-point increase | | | 0.79 (0.75, 0.83) | –19.3 (–24.1, –14.4) | |
| PRS (per 10 percentile increase) | | | 1.13 (1.11, 1.15) | | |

Table S8 Continued

| Variables | CRC cases, <i>n</i> (%) | Controls, <i>n</i> (%) | OR (95% CI) ¹ | GRE (95% CI) | <i>P</i> -interaction ² |
|----------------------------------|-------------------------|------------------------|--------------------------|-----------------------|------------------------------------|
| Female | | | | | 0.80 |
| Healthy lifestyle score | | | | | |
| 0–2 | 365 (19.4) | 177 (11.7) | Ref. | Ref. | |
| 3 | 649 (34.5) | 457 (30.2) | 0.71 (0.56, 0.90) | –28.0 (–48.1, –8.0) | |
| 4 | 641 (34.1) | 551 (36.5) | 0.58 (0.46, 0.73) | –44.6 (–65.8, –23.3) | |
| 5 | 227 (12.1) | 326 (21.6) | 0.36 (0.28, 0.48) | –83.6 (–111.9, –55.3) | |
| Per 1-point increase | | | 0.75 (0.69, 0.81) | –23.5 (–31.6, –15.5) | |
| PRS (per 10 percentile increase) | | | 1.13 (1.10, 1.16) | | |
| Male | | | | | |
| Healthy lifestyle score | | | | | |
| 0–2 | 1,154 (39.4) | 699 (28.8) | Ref. | Ref. | |
| 3 | 1,066 (36.4) | 880 (36.2) | 0.81 (0.70, 0.93) | –17.2 (–29.4, –5.1) | |
| 4 | 592 (20.2) | 624 (25.7) | 0.66 (0.56, 0.78) | –34.0 (–48.6, –19.4) | |
| 5 | 120 (4.1) | 227 (9.3) | 0.38 (0.29, 0.50) | –79.2 (–104.8, –53.5) | |
| Per 1-point increase | | | 0.80 (0.75, 0.84) | –18.3 (–23.9, –12.6) | |
| PRS (per 10 percentile increase) | | | 1.13 (1.11, 1.16) | | |

¹Variables in the model included the healthy lifestyle score, age, gender, education, family history of CRC, history of colonoscopy, participation in routine health check-ups, use of nonsteroidal anti-inflammatory drugs, and PRS (per 10 percentiles, continuous) but without the stratification factors. ²Interactions were tested by inclusion of a cross-product term of the healthy lifestyle score (categorical variable) and stratification factors in the models. CI, confidence intervals; CRC, colorectal cancer; GRE, genetic risk equivalent; OR, odds ratio; PRS, polygenic risk score; Ref., reference.

Table S9 Associations of the healthy lifestyle score with CRC risk, stratified by history of colonoscopy, use of NSAIDs, and family history of CRC

| Healthy lifestyle score | CRC cases, <i>n</i> (%) | Controls, <i>n</i> (%) | OR (95% CI) ¹ | GRE (95% CI) | <i>P</i> -interaction ² |
|------------------------------------|-------------------------|------------------------|--------------------------|----------------------|------------------------------------|
| History of colonoscopy: no | | | | | 0.22 |
| Healthy lifestyle score | | | | | |
| 0–2 | 1,155 (32.6) | 352 (22.4) | Ref. | Ref. | |
| 3 | 1,259 (35.5) | 514 (32.8) | 0.77 (0.65, 0.90) | –19.9 (–32.9, –7.0) | |
| 4 | 878 (24.8) | 483 (30.8) | 0.58 (0.49, 0.69) | –41.6 (–56.7, –26.5) | |
| 5 | 250 (7.1) | 219 (14.0) | 0.38 (0.30, 0.48) | –73.8 (–95.5, –52.2) | |
| Per 1-point increase | | | 0.76 (0.71, 0.80) | –20.9 (–26.8, –15.1) | |
| PRS (per 10 percentile increase) | | | 1.14 (1.12, 1.17) | | |
| History of colonoscopy: yes | | | | | |
| Healthy lifestyle score | | | | | |
| 0–2 | 364 (28.6) | 524 (22.1) | Ref. | Ref. | |
| 3 | 456 (35.8) | 823 (34.7) | 0.79 (0.66, 0.95) | –20.8 (–37.7, –3.9) | |

Table S9 Continued

| Healthy lifestyle score | CRC cases, <i>n</i> (%) | Controls, <i>n</i> (%) | OR (95% CI) ¹ | GRE (95% CI) | <i>P</i> -interaction ² |
|-----------------------------------|-------------------------|------------------------|--------------------------|------------------------|------------------------------------|
| 4 | 355 (27.9) | 692 (29.2) | 0.71 (0.58, 0.86) | -30.2 (-48.8, -11.6) | |
| 5 | 97 (7.6) | 334 (14.1) | 0.39 (0.30, 0.52) | -83.1 (-113.9, -52.3) | |
| Per 1-point increase | | | 0.81 (0.75, 0.86) | -18.6 (-26.0, -11.2) | |
| PRS (per 10 percentile increase) | | | 1.12 (1.09, 1.15) | | |
| Use of NSAIDs: no | | | | | 0.55 |
| Healthy lifestyle score | | | | | |
| 0-2 | 1,039 (30.3) | 503 (20.6) | Ref. | Ref. | |
| 3 | 1,197 (34.9) | 803 (32.9) | 0.77 (0.66, 0.90) | -19.9 (-32.1, -7.8) | |
| 4 | 927 (27.0) | 741 (30.4) | 0.64 (0.55, 0.75) | -34.1 (-47.4, -20.7) | |
| 5 | 264 (7.7) | 392 (16.1) | 0.36 (0.29, 0.45) | -78.0 (-98.2, -57.8) | |
| Per 1-point increase | | | 0.76 (0.72, 0.81) | -20.9 (-26.3, -15.6) | |
| PRS (per 10 percentile increase) | | | 1.14 (1.12, 1.16) | | |
| Use of NSAIDs: yes | | | | | |
| Healthy lifestyle score | | | | | |
| 0-2 | 480 (34.6) | 373 (24.8) | Ref. | Ref. | |
| 3 | 518 (37.3) | 534 (35.6) | 0.80 (0.65, 0.97) | -19.7 (-38.0, -1.4) | |
| 4 | 306 (22.1) | 434 (28.9) | 0.61 (0.49, 0.76) | -43.6 (-66.5, -20.7) | |
| 5 | 83 (6.0) | 161 (10.7) | 0.46 (0.33, 0.63) | -68.5 (-102.5, -34.6) | |
| Per 1-point increase | | | 0.80 (0.74, 0.87) | -19.7 (-28.3, -11.1) | |
| PRS (per 10 percentile increase) | | | 1.12 (1.08, 1.15) | | |
| Family history of CRC: no | | | | | 0.0013 |
| Healthy lifestyle score | | | | | |
| 0-2 | 1,281(31.1) | 801 (22.8) | Ref. | Ref. | |
| 3 | 1,449 (35.3) | 1,192 (33.9) | 0.80 (0.70, 0.91) | -18.3 (-29.2, -7.3) | |
| 4 | 1,075 (26.2) | 1,028 (29.3) | 0.69 (0.60, 0.79) | -30.4 (-42.6, -18.1) | |
| 5 | 305 (7.4) | 491 (14.0) | 0.42 (0.35, 0.51) | -71.0 (-89.6, -52.4) | |
| Per 1-point increase | | | 0.80 (0.76, 0.84) | -18.3 (-23.0, -13.5) | |
| PRS (per 10 percentile increase) | | | 1.13 (1.11, 1.15) | | |
| Family history of CRC: yes | | | | | |
| Healthy lifestyle score | | | | | |
| 0-2 | 238 (33.8) | 75 (17.4) | Ref. | | |
| 3 | 266 (37.8) | 145 (33.8) | 0.61 (0.42, 0.87) | -31.5 (-56.6, -6.4) | |
| 4 | 158 (22.4) | 147 (34.3) | 0.32 (0.22, 0.47) | -72.6 (-105.1, -40.0) | |
| 5 | 42 (6.0) | 62 (14.5) | 0.20 (0.11, 0.33) | -102.5 (-148.3, -56.7) | |

Table S9 Continued

| Healthy lifestyle score | CRC cases, <i>n</i> (%) | Controls, <i>n</i> (%) | OR (95% CI) ¹ | GRE (95% CI) | <i>P</i> -interaction ² |
|----------------------------------|-------------------------|------------------------|--------------------------|----------------------|------------------------------------|
| Per 1-point increase | | | 0.59 (0.51, 0.68) | -33.6 (-47.0, -20.2) | |
| PRS (per 10 percentile increase) | | | 1.17 (1.11, 1.23) | | |

¹Variables in the model included healthy lifestyle scores, age, gender, education, family history of CRC, history of colonoscopy, participation in routine health check-ups, use of NSAIDs, and PRS (per 10 percentiles, continuous), but without the stratification factors. ²Interactions were tested by inclusion of a cross-product term of the healthy lifestyle score (categorical variable) and stratification factors in the models. CI, confidence intervals; CRC, colorectal cancer; GRE, genetic risk equivalent; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PRS, polygenic risk score; Ref., reference.